Evofem Biosciences Reports $16.5M Loss, Warns of Going Concern Doubt

summarizeSummary

Evofem Biosciences reported a $16.5 million net loss for H1 2026 and warned that its cash is insufficient to fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.

check_boxKey Events · Earnings and Guidance · EVFM

• Going Concern Warning

  Management states liquidity resources are insufficient to fund operations for the next 12 months, raising substantial doubt about the company's ability to continue as a going concern.

• Net Loss Widens

  Net loss was $16.5 million for the six months ended June 30, 2026, compared to $0.8 million in the prior-year period.

• Working Capital Deficit

  Working capital deficit of $82.5 million and accumulated deficit of $914.0 million as of June 30, 2026.

• Non-Cash Fair-Value Loss

  Derivative liabilities increased from $1.0 million to $6.9 million, driven by a $5.9 million non-cash fair-value loss on purchase rights.

auto_awesomeAnalysis · EVFM · Life Sciences

Evofem Biosciences disclosed a $16.5 million net loss for the first half of 2026 and stated that its cash resources are insufficient to fund operations for the next 12 months. The company has a working capital deficit of $82.5 million and an accumulated deficit of $914 million. Management concluded that these conditions raise substantial doubt about the company's ability to continue as a going concern. The loss was driven by a 38% decline in product sales, a $5.9 million non-cash fair-value loss on derivative liabilities, and a $2.2 million loss on debt extinguishment. The company also continues to have unremediated material weaknesses in internal controls. This filing is critical because it confirms the company's financial distress and the risk of insolvency.